Readministration of abciximab: Interim report of the ReoPro readministration registry

American Heart Journal

Volumn 138, Issue 1 II, 1999, Pages

  Tcheng, J E ^a   Kereiakes, D J ^a   Braden, G A ^a   Jordan, R E ^a   Mascelli, M A ^a   Langrall, M A ^a   Effron, M B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CHIMERIC ANTIBODY; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGENICITY; BLEEDING; BRAIN HEMANGIOMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG REEXPOSURE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032767448     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1999.v138.99236     Document Type: Conference Paper

References (17)

1. American Heart Association. 1999 Heart and stroke statistical update. Available at: http://www.americanheart.org/statistics.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
4. Lindahl B, Andren B, Ohlsson J, et al. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
5. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
6. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: the IMPACT-II trial. Lancet 1997;349:1422-8.
7. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
8. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
9. 3. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker, Inc; 1997. p. 291-313.
10. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8.
11. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
12. Fry ETA, Hermiller JB, Peters TF, et al. Safety and efficacy of repeat administration of abciximab (ReoPro) is equivalent to initial treatment [abstract]. Circulation 1997;96:I-161-2.
13. Madan M, Kereiakes DJ, Rund M, et al. Abciximab readministration: Is it safe? [abstract]. Circulation 1997;96:I-162.
14. Crowther MA, Ginsburg JS. Direct thrombin inhibitors in venous thromboembolism. In: Sasahara AA, Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker, Inc; 1997. p. 159-68.
15. Physician's Desk Reference, 53rd ed. Montvale, NJ: Medical Economics Company; 1999. p. 2160-4
16. Cytogen Corporation. Products: human antimurine antibody (HAMA). Available from: http://cytogen.com/products-mstr.htm
17. Abramowicz M. Two new antiplatelet drugs for angioplasty and acute coronary syndromes. Med Lett 1998;40:89-90.